Regarding the abnormal astroglia activation response as a pathological pathway involved in neurodegenerative diseases, the glial fibrillary acidic protein (GFAP) plasma biomarker has been studied in Alzheimer’s disease [23,24,25,26]. The gene discussed is GFAP; the disease is early-onset autosomal dominant Alzheimer disease.